



1 May

1644/\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 36119.125US10)

In re Application of: June et al.) Examiner: Gambel
Serial No. 09/349,915) Group Art Unit: 1644
Filing Date: July 8, 1999) Cust. No. 23483

For: METHODS FOR SELECTIVELY STIMULATING PROLIFERATION OF T CELLS

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below.

Date: 5/10/04

Sarah Farris
Sarah Farris

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed for filing in the above-identified patent application are the following items:

1. Supplemental Information Disclosure Statement (2 pages);
2. Form PTO-1449 (2 Pages) Citing 30 References;
3. Copies of Cited References;
4. Payment of \$180.00 Fee (*deposit account authorization below*);
5. Certificate of First Class Mailing; and
6. Return Postcard.

Please charge the \$180.00 fee to Deposit Account No. 08-0219. Please also charge any additional fees that might be due or credit any overpayment to our Deposit Account No. 08-0219.

Respectfully submitted,

Colleen Superko
Colleen Superko, Reg. No. 39,850

Date: May 10, 2004

HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6564
(617) 526-5000 (Facsimile)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 36119.125US10)

In re Application of: June et al.) Examiner: Gambel
Serial No. 09/349,915) Group Art Unit: 1644
Filing Date: July 8, 1999) Cust. No. 23483

For: METHODS FOR SELECTIVELY STIMULATING PROLIFERATION OF T CELLS

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below.

Date: 5/10/04

Sarah Farris

Sarah Farris

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith the references on the attached Form PTO-1449, copies of which are also attached. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97 (c) (2), after the mailing of a Final Office Action on the merits. Pursuant to 37 C.F.R. § 1.97 (e)(2), the \$180.00 fee should be charged to Deposit Account No. 08-0219.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to the patentability of the invention, or that the listed documents are prior art. Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents constitute prior art under United States law, Applicants reserve the right to present to the Office relevant facts and law regarding the significance of such documents to the patentability of the claimed invention.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449 with the next Patent Office communication.

05/12/2004 ZJUHAR1 00000077 080219 09349915

01 FC:1806 180.00 DA

BOSTON I906935v1

Supplemental Information Disclosure Statement
Appln. No. 09/349,915
Page 2

Please charge any additional fees that might be due or credit any overpayment to Deposit
Account Number 08-0219. If there are any questions, please call the undersigned at the telephone number
indicated below.

Respectfully submitted,

A handwritten signature in cursive script, reading "Colleen Superko", written over a horizontal line.

Colleen Superko, Reg. No. 39,850

Date: May 10, 2004

HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6564
(617) 526-5000 (Facsimile)

Subt. For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Sheet 1 OF 2

Docket Number
36119.125 US10Application Number
09/349,915Applicant
June et al.Filing Date
July 8, 1999Group Art Unit
1644

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,081,029	Jan 14, 1992	Zarling et al.			
	5,500,348	Mar 19, 1996	Nishimura et al.			
	5,858,358	Jan 12, 1999	June et al.			
	6,010,902	Jan 4, 2000	Ledbetter et al.			
	6,352,694	Mar 5, 2002	June et al.			
	6,534,055	Mar 18, 2003	June et al.			

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

A1	Boucheix, C. et al., "Molecular Cloning of the CD9 Antigen," The Journal of Biological Chemistry, Vol. 266, No. 1, pp. 117-122 (1991)
A2	Carroll et al., "Stimulus-response Coupling in Human Platelets Activated by Monoclonal Antibodies to the CD9 Antigen, a 24 kDa Surface Membrane Glycoprotein," Biochem. J., Vol. 266, pp. 527-535 (1990)
A3	Chow et al. Nature, Vol. 361, pp. 650-654 (1993)
A4	Fahey et al. Clin. Exp. Immunol. Vol. 88, pp. 1-5 (1992)
A5	Garbrecht, et al. J. Immunol. Methods. Vol. 107, pp. 137-142 (1988)
A6	Guinan et al. Blood, Vol. 84, pp. 3261-3282 (1994)
A7	Haynes, Ann. Med. Vol. 28, pp. 39-41 (1996)
A8	Hirsch, New England J. Med., Vol. 328, pp. 1686-1695 (1993)
A9	Kalinski et al., "Functional Maturation of Human Naïve T Helper Cells in the Absence of Accessory Cells." The Journal of Immunology, Vol. 154, pp. 3753-3760 (1995)
A10	Kmieciak. American Scientist. Vol. 87, pp. 240-247 (1999)
A11	Lanza et al., "cDNA Cloning and Expression of Platelet p24/CD9" Journal of Biological Chemistry, Vol. 266, No. 16, pp. 10638-10645 (1991)
A12	Ledbetter et al., PNAS, Vol. 85, pp. 8628-8632 (1988)
A13	Lederman et al., Molecular Immunology, Vol. 18, pp. 1171-1181 (1991)
A14	Li et al., PNAS, Vol. 77, pp. 3211-3214 (1990)
A15	Lyerly et al. AIDS Research and Human Retroviruses (Abstract only) Vol. 3, pp. 87-94
A16	Malim et al. J. Exp. Med. Vol. 176, pp. 1197-1201 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Subt. For, PTO-1449

**INFORMATION DISCLOSURE
IN AN APPLICATION***(Use several sheets if necessary)*Docket Number
36119.125 US10Application Number
09/349,915Applicant
June et al.Filing Date
July 8, 1999Group Art Unit
1644

	A17	Ngo et al. "In the Protein Folding-Problem and Tertiary Structure Prediction," Merz et al. (ed.) (1994)
	A18	Perno et al. J. Exp. Med. Vol. 168, pp. 1111-1116 (1988)
	A19	Roederer et al. J.Clin. Invest. Vol. 99, pp. 1555-1564 (1997)
	A20	Scadden, J. Acquired Immune Deficiency Syndrome and Human Retrovirology Vol. 16 (Suppl. 1) pp. S23-S29
	A21	Skolnick. Trends in BioTech., Vol. 18, pp. 34-39 (2000)
	A22	Van Noesel et al. J. Clin. Invest. Vol. 86, pp. 293-299 (1990)
	A23	Verma, et al. Nature, Vol. 389, pp. 239-242 (1997)
	A24	Zola, et al., "The p24 Leucocyte Membrane Antigen: Modulation Associate with Lymphocyte Activation and Differentiation," Immunol. Cell Biol., Vol. 67, pp. 63-70 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.